Wird geladen...
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for patients who are...
Gespeichert in:
| Veröffentlicht in: | Cochrane Database Syst Rev |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons, Ltd
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478267/ https://ncbi.nlm.nih.gov/pubmed/28453187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub2 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|